2013 American Society of Hematology Annual Meeting*

December 7-10, 2013; New Orleans, Louisiana
CCO’s Independent Conference Coverage of the 2013 American Society of Hematology annual meeting includes Capsule Summaries of key studies plus expert analyses of new clinical trial findings with downloadable highlights slidesets. Topics include chronic lymphocytic leukemia and other B-cell malignancies, chronic myeloid leukemia, myelodysplastic syndromes and acute leukemias, and multiple myeloma.

Multiple Myeloma

Capsules

Refractory patients previously treated with PIs, IMiDs, or both showed ORRs above 65%.

Released: December 9, 2013

Ixazomib, either alone or in combination with dexamethasone, produced a PR or better in approximately one third of patients with relapsed MM and limited previous exposure to bortezomib in this phase II trial.

Released: December 9, 2013

Continuous lenalidomide plus low-dose dexamethasone significantly extended PFS and OS in transplantation-ineligible patients with newly diagnosed MM.

Released: December 11, 2013

Adding afuresertib to bortezomib and dexamethasone may overcome bortezomib resistance.

Released: December 12, 2013

Anti-CD38 antibody at ≥ 10 mg/kg achieved an ORR of 30.9% in patients with CD38+ hematologic malignancies.

Released: December 11, 2013

Long-term outcome of patients presenting with renal failure significantly improved with bortezomib-based induction and maintenance therapy vs vincristine/thalidomide regimen with fewer discontinuations of maintenance therapy due to toxicity.

Released: December 12, 2013

This final analysis confirms previously demonstrated significant PFS and OS benefits with POM plus LoDEX vs high-dose dexamethasone in a patient population with relapsed/refractory MM. High‐risk cytogenetics did not impact median PFS for patients receiving POM plus LoDEX. In this heavily pretreated population, 9% of POM plus LoDEX patients had a duration of therapy (DoT) > 12 months.

Released: December 11, 2013

In this phase I/II study, twice-weekly dosing of ixazomib in combination with lenalidomide/dexamethasone was feasible and active

Released: December 13, 2013

Despite similar response rates and survival, MPR had a worse safety profile compared with CPR and Rd, including higher rates of hematologic adverse events, in this phase III trial.

Released: December 12, 2013

When used in both induction and consolidation, combination carfilzomib/thalidomide/dexamethasone produced responses in 96% of patients, including very good PR or better in 84%.

Released: December 11, 2013
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
Celgene Corporation
Genentech BioOncology
Gilead Sciences
Takeda Oncology
Novartis Oncology
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?